Nymox Pharmaceutical has announced today that patient dosing in the company's multicenter Phase II clinical trial of NX-1207 is completed this week. NX-1207 is the company's lead drug candidate for the treatment of benign prostatic hyperplasia (BPH), a common affliction of men over the age of 50.
To date, regular reviews of safety data for the trial have revealed no serious drug side effects from NX-1207 treatment. Two earlier completed Phase I and II trials of NX-1207 showed that the drug produced on average over 23 percent prostate shrinkage and significant symptomatic improvement in one month with minimal side effects. Overall there were no sexual side effects, and a better side effect profile compared to existing drugs.